Getinge (GETI.B) AI Stock Analysis

• Market Cap: kr57.12B
• Dividend Yield: 2.19%
• Average Volume (3M): 582.41K
• Price to Earnings (P/E): 38.0
• Beta (1Y): 0.89
• Revenue Growth: 6.51%
• EPS Growth: -42.34%
• Country: SE
• Employees: 11,827
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Devices
• EPS (TTM): 2.25
• Shares Outstanding: 254,152,370
• 10 Day Avg. Volume: 442,620
• 30 Day Avg. Volume: 582,415
• PEG Ratio: -0.94
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 1.42
• P/FCF Ratio: 15.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr198.25
• Price Target Upside: -3.86% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 68 Neutral
• Price Target: kr212.00 ▲(2.81% Upside)

Getinge's overall stock score is driven primarily by its stable financial performance and positive technical indicators. The company's consistent profitability and improving cash flow are strengths, but the decline in revenue growth and high P/E ratio are concerns. The technical analysis suggests a positive trend, while the valuation indicates potential overvaluation.

Getinge Business Overview & Revenue Model

Company Description

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, logistic automation solutions, bioreactors, bioprocess control systems, bioprocess software, biobundles, bioprocess analytics, and perfusion systems; practice-oriented monitoring systems and disposables, anesthesia machines, beating heart stabilizers and positioners, axius blower mister and coronary shunts, proximal seal systems, ceiling supply units, connected solutions, cleaning and disinfection products, packaging and sealing solutions, monitors and indicators, and SteriTec products. The company also provides thoracic catheters, dry seal chest drain, mobile dry seal drain, dry and wet suction water seal chest drain, and chest drain valves; transitional accessories; endoscope reprocessing; endoscopic vessel harvesting systems; endovascular products; extracorporeal life support or extracorporeal membrane oxygenation products; inspection and packing products; intra-aortic balloon counter pulsation therapies; mechanical ventilation products; medical furniture; modular room systems; operating lights and tables; OR integration and management; patient flow management; patient transport; sterile supply management; sterilization; surgical assist systems; surgical perfusion; transport & storage; trays & baskets; and vascular and cardiothoracic surgery solutions. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.

How the Company Makes Money

Getinge generates revenue through the sale of medical devices, equipment, and related services within its core segments. The Acute Care Therapies division, which includes products such as ventilators, cardiopulmonary devices, and perfusion systems, represents a significant revenue stream, particularly in critical care settings. The Surgical Workflows segment contributes through the sale of surgical instruments, operating room equipment, and sterilization systems. Additionally, the company benefits from recurring revenue through service contracts, maintenance, and parts supply for its devices. Strategic partnerships and collaborations with hospitals, healthcare providers, and research institutions also enhance its market presence and drive sales, particularly in emerging markets where healthcare infrastructure is expanding.

Getinge Financial Statement Overview

Summary

Getinge's financial performance is solid, with consistent revenue growth and stable profitability. The company maintains a balanced financial structure, though increased leverage and reduced returns on equity could pose risks. Cash flow generation is strong despite a decline in free cash flow.

Income Statement

Getinge demonstrates solid profitability with a strong gross profit margin of approximately 46% and a respectable net profit margin of around 4.2% for TTM. However, both EBIT and EBITDA margins have slightly contracted compared to previous years. Revenue growth is healthy, with a year-over-year increase of 2.3% in the TTM. The company exhibits moderate revenue growth and stable profitability, though declining EBIT margins may require attention.

Balance Sheet

The balance sheet reveals a stable financial structure with an equity ratio of about 50.7%, indicating a balanced asset financing strategy. However, the debt-to-equity ratio has increased to 0.38, reflecting higher leverage compared to prior years. Return on equity stands at 4.8% for the TTM, showing a reduction from previous periods, which suggests potential challenges in generating returns on equity.

Cash Flow

Cash flow analysis indicates a decline in free cash flow growth, with a negative growth rate of approximately -24% compared to the previous annual report. The operating cash flow to net income ratio is robust at 2.57, highlighting efficient cash generation relative to net income. Despite the decline in free cash flow, the company maintains a healthy cash conversion efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	35.50B	34.76B	31.83B	28.29B	27.05B	29.82B
Gross Profit	16.64B	16.15B	14.49B	13.41B	13.58B	14.72B
EBITDA	6.37B	5.31B	5.93B	5.73B	6.20B	6.46B
Net Income	1.49B	1.64B	2.41B	2.49B	2.97B	3.24B
Balance Sheet
Total Assets	56.37B	63.92B	53.59B	52.03B	44.55B	45.01B
Cash, Cash Equivalents and Short-Term Investments	1.95B	2.96B	2.73B	5.68B	4.08B	6.06B
Total Debt	11.17B	10.73B	8.08B	5.82B	4.31B	10.21B
Total Liabilities	27.35B	30.71B	23.18B	21.58B	19.38B	23.53B
Stockholders Equity	28.82B	33.01B	30.17B	30.04B	24.75B	21.02B
Cash Flow
Free Cash Flow	2.70B	3.27B	1.60B	2.23B	5.63B	6.15B
Operating Cash Flow	4.03B	4.58B	2.96B	3.37B	6.56B	7.20B
Investing Cash Flow	-5.85B	-4.55B	-6.54B	-1.47B	-1.33B	-1.99B
Financing Cash Flow	1.50B	504.00M	511.00M	-500.00M	-7.24B	-297.00M

Getinge Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 206.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GETI.B, the sentiment is Positive. The current price of 206.2 is above the 20-day moving average (MA) of 201.25, above the 50-day MA of 195.22, and above the 200-day MA of 191.69, indicating a bullish trend. The MACD of 3.83 indicates Negative momentum. The RSI at 59.65 is Neutral, neither overbought nor oversold. The STOCH value of 53.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:GETI.B.

Getinge Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GETI.B	68 Neutral	kr57.12B	37.97	4.94%	2.19%	6.51%	-42.34%
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%
0YAY	―	kr18.33B	40.64	3.46%	5.60%	―	―
CLVSF	―	$445.75M	30.66	18.65%	1.24%	―	―
XVIPF	―	$586.37M	53.99	5.17%	―	―	―
61L0	―	€6.06B	120.09	32.07%	―	―	―
7D2A	―	€145.23M	―	-5.40%	―	―	―

Getinge Corporate Events

Getinge’s Cardiosave Intra-Aortic Balloon Pump CE Mark Reinstated

Getinge has announced that the EU CE Mark for its Cardiosave Intra-Aortic Balloon Pump has been reinstated by the EU Notified Body TÜV SÜD after addressing compliance gaps and implementing design improvements. This reinstatement allows Getinge to resume deliveries of the device to markets accepting the CE mark, ensuring healthcare professionals and patients have access to this critical cardiac care device.

The most recent analyst rating on ($SE:GETI.B) stock is a Sell with a SEK180.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.

Getinge Announces Q2 2025 Report and Conference Call

Getinge has announced its Q2 Report 2025 will be released on July 18, 2025, followed by a conference call hosted by the company’s President & CEO and CFO. This event invites fund managers, analysts, and media to participate, potentially impacting stakeholders by providing insights into the company’s financial performance and strategic direction.

The most recent analyst rating on ($SE:GETI.B) stock is a Sell with a SEK190.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.